[Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
vom Dahl
J
J
Medizinische Klinik I, Universitätsklinikum Aachen.
Schotten
U
U
Sasse
A
A
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017298:Bisoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000077261:Carvedilol; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D015201:Meta-Analysis as Topic; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002227:Carbazoles; D010919:Placebos; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol; D017298:Bisoprolol